RADX vs ARTV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ARTV Captures Institutional Edge (2โ1 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Artiva Biotherapeutics, Inc. Common Stock (ARTV) driven by superior Growth & Margin, Momentum & Technical while RADX counters with relative strength in Options & Structure. Fundamentally, RADX trades at N/M Forward P/E with -411.6% operating margin (-36.9% YoY revenue) versus ARTV at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ARTV sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RADX | ARTV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $10.6M | $189.3M | Larger Scale | ARTV |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -36.9% | -100.0% | Higher Growth | RADX |
| Operating Margin (TTM) Profitability | -411.6% | 0.0% | Higher Margin | ARTV |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -174.7% | -43.6% | Higher ROE | ARTV |
| 52-Week Range Position Momentum | 0% ($1โ$16) | 7% ($3โ$15) | Stronger Trend | ARTV |
| Beta / 30D Volatility Risk Regime | 0.52ฮฒ ยท 109% Vol | 1.52ฮฒ ยท 104% Vol | Lower Realized Risk | ARTV |
| Unified Institutional Score Composite Signal | 41.1 / 100 (SELL) | 54.0 / 100 (HOLD) | Higher Composite | ARTV |